Bibliometric analysis of global research hotspots in ovarian cancer immunotherapy from 2014 to 2024 using CiteSpace
Related Experiment Video
Updated: Sep 16, 2025

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
Published on: April 18, 2025
Zhuo Zhang1, Datian Fu2, Yingdong Cao2
1Department of Radiotherapy, Hainan Cancer Hospital, Haikou, Hainan, China.
Bibliometric analysis has been employed to systematically evaluate the research landscape and emerging trends in ovarian cancer immunotherapy over the past decade (2014-2024). A bibliometric analysis of 3,100 publications (including reviews articles and articles) on immunotherapeutic interventions for ovarian malignancies was conducted using the Web of Science Core Collection (2014-2024). Temporal publication trends, institutional collaboration networks, and emerging research foci were systematically examined via CiteSpace software. A total of 3381 articles on ovarian cancer immunotherapy were initially identified, with 3100 records meeting the inclusion criteria for final analysis. The United States (n = 1,076) to become the major contributors of this field, with the University of Texas System (n = 131) being the most prolific institution. Among individual researchers, Odunsi, Kunle (n = 32) were the most extensively published authors. The most frequently cited reference was Matulonis UA (2019), with 235 citations. Co-citation cluster analysis revealed seven major research themes: expression, parp inhibitors, cancer immunotherapy, endometrial cancer, ovarian cancer, tumor associated antigens, chimeric antigen receptor. Parp inhibitors, tumor-associated antigens, and CAR-based therapies constituting critical themes for ovarian cancer research. Keyword burst detection identified emerging foci: dendritic cell, adoptive cell transfer, and regulatory T cell. These approaches offer promise for countering the TME characteristic of ovarian cancer, thereby enabling enhanced therapeutic efficacy. Prominent universities and developed nations form the finest alliances for research on immunotherapy for ovarian cancer. Three core research clusters are identified: dendritic cell-based therapies, adoptive immunotherapy, and tumor-infiltrating lymphocyte applications. These findings delineate the field's evolving trajectory and offer strategic directions for future investigations, emphasizing translational potential and multidisciplinary integration.
Bibliometric analysis has been employed to systematically evaluate the research landscape and emerging trends in ovarian cancer immunotherapy over the past decade (2014-2024). A bibliometric analysis of 3,100 publications (including reviews articles and articles) on immunotherapeutic interventions for ovarian malignancies was conducted using the Web of Science Core Collection (2014-2024). Temporal publication trends, institutional collaboration networks, and emerging research foci were systematically examined via CiteSpace software. A total of 3381 articles on ovarian cancer immunotherapy were initially identified, with 3100 records meeting the inclusion criteria for final analysis. The United States (n = 1,076) to become the major contributors of this field, with the University of Texas System (n = 131) being the most prolific institution. Among individual researchers, Odunsi, Kunle (n = 32) were the most extensively published authors. The most frequently cited reference was Matulonis UA (2019), with 235 citations. Co-citation cluster analysis revealed seven major research themes: expression, parp inhibitors, cancer immunotherapy, endometrial cancer, ovarian cancer, tumor associated antigens, chimeric antigen receptor. Parp inhibitors, tumor-associated antigens, and CAR-based therapies constituting critical themes for ovarian cancer research. Keyword burst detection identified emerging foci: dendritic cell, adoptive cell transfer, and regulatory T cell. These approaches offer promise for countering the TME characteristic of ovarian cancer, thereby enabling enhanced therapeutic efficacy. Prominent universities and developed nations form the finest alliances for research on immunotherapy for ovarian cancer. Three core research clusters are identified: dendritic cell-based therapies, adoptive immunotherapy, and tumor-infiltrating lymphocyte applications. These findings delineate the field's evolving trajectory and offer strategic directions for future investigations, emphasizing translational potential and multidisciplinary integration.
More Related Videos
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Survival Analysis